Sürdürülebilir Kalkınma Amaçları
Yazarlar
- Attar, Rukset(2)
- Ozbey, Ulku(2)
- Afshar, Behnaz(1)
- Alhewairini, Saleh S(1)
- Aslan, Naim(1)
- Barber, Asa H.(1)
- Farooqi, Ammad A.(1)
- Farooqi, Ammad Ahmad(1)
- Hanna-Wakim, Lara(1)
- Kao, Alexander P.(1)
- Koç, Mümin Mehmet(1)
- Lin, Xiukun(1)
- Nurmurzayevich, Sadykov B.(1)
- Ozcelik, Beraat(1)
- Ozturk, Ozlem(1)
- Qureshi, Muhammad Z.(1)
- Romero, Mirna A.(1)
- Romero, Mirna Azalea(1)
- Sabitaliyevich, Uteuliyev Y.(1)
- Uteuliev, Yerzhan Sabitaliyevich(1)
- Wakim, Lara H.(1)
- Yelekenova, Armida Bakhytbekovna(1)
Yayınlar
- MakaleYalnız künye2019Scopus SJRQ2Regulation of signaling pathways by β-elemene in cancer progression and metastasis
Qureshi, Muhammad Z.; Attar, Rukset; Romero, Mirna A.; Sabitaliyevich, Uteuliyev Y.; Nurmurzayevich, Sadykov B.; Ozturk, Ozlem; Wakim, Lara H.; Lin, Xiukun; Ozbey, Ulku; Yelekenova, Armida Bakhytbekovna
Entry of β-elemene into various phases of clinical trials advocates its significance as a premium candidate likely to gain access to mainstream medicine. Based on the insights gleaned from decades of research, it seems increasingly transparent that β-elemene has shown significant ability to modulate multiple cell signaling pathways in different cancers. We partition this multicomponent review into how β-elemene strategically modulates various signal transduction cascades. We have individually summarized regulation of tumor necrosis factor related apoptosis-inducing ligand, signal transducers and activators of transcription, transforming growth factor/SMAD, NOTCH, and mammalian target of rapamycin pathways by β-elemene. Last, we will discuss the results of clinical trials of β-elemene and how effectively we can use these findings to stratify patients who can benefit most from β-elemene.
AtıfScopus33OpenAlex33
İncele - MakaleYalnız künye2019Scopus SJRQ2Apigenin as an effective anticancer natural product: Spotlight on TRAIL, WNT/β-catenin, JAK-STAT pathways, and microRNAs
Ozbey, Ulku; Attar, Rukset; Romero, Mirna Azalea; Alhewairini, Saleh S; Afshar, Behnaz; Uteuliev, Yerzhan Sabitaliyevich; Hanna-Wakim, Lara; Ozcelik, Beraat; Farooqi, Ammad Ahmad
Wealth of information gleaned from decades of high-impact research work; scientists have disentangled the complicated web of versatile regulators that underlie cancer development and progression. Use of structural biology approaches and functional genomics have helped us to gain new insights into complex nature of cancer, and it is now clear that genetic/epigenetic mutations, overexpression of oncogenes, inactivation of tumor suppressors, loss of apoptosis, and versatility of protein binding partners have contributory roles in carcinogenesis and metastatic spread. It is becoming progressively more understandable that reprogramming of gene expression during and nontranscriptional changes during cancer development and progression are initiated and controlled by deregulated signal transduction cascades, all of which collectively create an incalculable complexity. Data obtained through preclinical and clinical trials revealed that alterations in the targeted oncogenes and other downstream, and parallel pathways played a central role in the development of resistance against different therapeutics. Phytochemicals have regained limelight, and different natural products are currently being tested for efficacy in preclinical studies. Apigenin, a plant-derived flavonoid has considerable pharmacological value and is reportedly involved in the regulation of different signaling cascades. In this review, we have attempted to summarize rapidly evolving understanding of molecular biologists and pharmacologists about the potential of apigenin in the regulation of deregulated signaling pathways in different cancers. We have emphasized on the regulation of WNT/β-catenin and janus kinase/signal transducers and activators of transcription (JAK-STAT) pathways. We also comprehensively discuss how apigenin restored apoptosis in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant cancers. The review also gives a snapshot of microRNAs (miRNAs) that regulate wide-ranging biological processes, and it is now clear that each miRNA can control hundreds of gene targets. Apigenin was noted to upregulate miR-520b and miR-101 in different cancers to inhibit tumor growth. Moreover, apigenin-induced apoptotic rate was significantly higher when used in combination with miR-423-5p inhibitors or miR-138 mimics. Better comprehension of linear and integrated signaling pathways will be helpful in effective therapeutic targeting of deregulated signaling pathways to inhibit/prevent cancer.
AtıfScopus65OpenAlex66İncele - Derleme MakaleAçık Erişim2019Scopus SJRQ2Evaluation of X-ray tomography contrast agents: A review of production, protocols, and biological applications
Koç, Mümin Mehmet; Aslan, Naim; Kao, Alexander P.; Barber, Asa H.
X-ray computed tomography is a strong tool that finds many applications both in medical applications and in the investigation of biological and nonbiological samples. In the clinics, X-ray tomography is widely used for diagnostic purposes whose three-dimensional imaging in high resolution helps physicians to obtain detailed image of investigated regions. Researchers in biological sciences and engineering use X-ray tomography because it is a nondestructive method to assess the structure of their samples. In both medical and biological applications, visualization of soft tissues and structures requires special treatment, in which special contrast agents are used. In this detailed report, molecule-based and nanoparticle-based contrast agents used in biological applications to enhance the image quality were compiled and reported. Special contrast agent applications and protocols to enhance the contrast for the biological applications and works to develop nanoparticle contrast agents to enhance the contrast for targeted drug delivery and general imaging applications were also assessed and listed.
AtıfScopus91OpenAlex101İncele - DergiJournal of Cellular Biochemistry